

Posteression	ID number	Title	First name	Middle name	Surname
Posteression A - Monday June 17, 17:30-18:30 hrs	24026	Untargeted omics and machine learning models identify CXCL7 CSF levels as a progression marker in sporadic Amyotrophic Lateral Sclerosis	Sergio		Roca-Pereira
Posteression A - Monday June 17, 17:30-18:30 hrs	24047	Cardiac Troponin T as a Serum Biomarker of Respiratory Impairment in Amyotrophic Lateral Sclerosis	Teresa		Koch
Posteression A - Monday June 17, 17:30-18:30 hrs	24054	VOE-ALS: a smartphone-based app for VOICE analysis in amyotrophic lateral sclerosis (ALS) patients	Myriam		Sposito
Posteression A - Monday June 17, 17:30-18:30 hrs	24076	The CSF in ALS – Inflammation and the blood-CSF barrier	Veronika		Klösch
Posteression A - Monday June 17, 17:30-18:30 hrs	24087	Lymphocyte subsets and psychiatric and cognitive outcomes in ALS patients	Yihan		Hu
Posteression A - Monday June 17, 17:30-18:30 hrs	24102	Neurofilament trafficking in SOD1-ALS patients treated with tofersen modeled by Quantitative Systems Pharmacology	Alessio		Paris
Posteression A - Monday June 17, 17:30-18:30 hrs	24105	Raised CSF UCHL1 in asymptomatic C9orf72 hexanucleotide repeat expansion carriers	Elizabeth		DeLlar
Posteression A - Monday June 17, 17:30-18:30 hrs	24113	Venous bicarbonate as a potential new prognostic biomarker for survival in amyotrophic lateral sclerosis clinical trials	Juliette		Foucher
Posteression A - Monday June 17, 17:30-18:30 hrs	24115	MultiOMIC biomarkers for ALS patients' prognostication	Yahel		Cohen
Posteression A - Monday June 17, 17:30-18:30 hrs	24130	Development of an exploratory electrophysiology endpoint for use in clinical development in amyotrophic lateral sclerosis	Kristina		Johnson
Posteression A - Monday June 17, 17:30-18:30 hrs	24139	Serum insulin-like growth factor proteins in amyotrophic lateral sclerosis	Linn		Gjerstedt
Posteression A - Monday June 17, 17:30-18:30 hrs	24147	Exploring osteopontin as a biomarker in the ALS-FTD spectrum	Tommaso		Russo
Posteression A - Monday June 17, 17:30-18:30 hrs	24164	Neurosteroid Profiles in the Cerebrospinal Fluid of Amyotrophic Lateral Sclerosis Patients	Cecilia		Simolini
Posteression A - Monday June 17, 17:30-18:30 hrs	24171	Interrogating the cortico-muscular communication in healthy participants using directed connectivity to develop neurophysiological biomarkers for ALS	Zahra		Eshagh Nimvari
Posteression A - Monday June 17, 17:30-18:30 hrs	24180	Gender specific differential expression of circRNAs in peripheral blood samples of ALS patients	Metka		Ravnik-Glavač
Posteression A - Monday June 17, 17:30-18:30 hrs	24182	Defining Patterns and Illustrating Disease Progression in ALS Using Electrical Engineering Methods of System Diagnostics	Ian		Wynyard
Posteression A - Monday June 17, 17:30-18:30 hrs	24183	Plasma cardiac troponin T is a biomarker for decreased heart rate variability in ALS patients	Alexander		Juto
Posteression A - Monday June 17, 17:30-18:30 hrs	24191	Metabolic and fluid biomarkers support a microglia-mediated inflammatory signature in ALS. The role of fluctuations in human motor axons: insights from low- and high-threshold motor units in patients with ALS and healthy controls	Alex		Bebeti
Posteression A - Monday June 17, 17:30-18:30 hrs	24217	Immunoprofiling of peripheral blood mononuclear cells in motor neuron diseases	Isabella		Busman
Posteression A - Monday June 17, 17:30-18:30 hrs	24219	High-throughput immunosay proteomics and machine learning analysis of longitudinal cerebrospinal fluid in amyotrophic lateral sclerosis	Carlotta		Kalßer
Posteression A - Monday June 17, 17:30-18:30 hrs	24233	Identification of miR-10b-5p as a potential miRNA signature in Amyotrophic Lateral Sclerosis Patients	David		Lester
Posteression A - Monday June 17, 17:30-18:30 hrs	24247	Higher MAP2 levels in CSF reflect strong somatodentritic degeneration in a larger cohort of ALS patients from two clinical centers	Banaja		Dash
Posteression A - Monday June 17, 17:30-18:30 hrs	24258	Cerebrospinal fluid levels of NIM in relation to NfL and pNfH as prognostic markers in amyotrophic lateral sclerosis	Patrick		Oeckl
Posteression A - Monday June 17, 17:30-18:30 hrs	24271	Exploring clinical chemistry markers in amyotrophic lateral sclerosis: insights into survival and disease trajectories	Jennie		Olofsson
Posteression A - Monday June 17, 17:30-18:30 hrs	24282	Biomarkers of Proteostasis Impairment in Amyotrophic Lateral Sclerosis	Ioannis		Psychgios
Posteression A - Monday June 17, 17:30-18:30 hrs	24285	Digital Measurement of Gait as a Potential Pharmacodynamic Biomarker for ALS-FTSD	Denis		Shevchuk
Posteression A - Monday June 17, 17:30-18:30 hrs	24342	Identification of novel neuronal markers associated with Extracellular Vesicles in Amyotrophic Lateral Sclerosis	HungMo		Kang
Posteression A - Monday June 17, 17:30-18:30 hrs	24348	Detection of Neurofilament Light chain in the tear fluid of patients with ALS	Luisa		Donini
Posteression A - Monday June 17, 17:30-18:30 hrs	24359	EEG activation patterns during a motor task in ALS	Antonia F.		Demleitner
Posteression A - Monday June 17, 17:30-18:30 hrs	24368	Assessing the Consistency of Speech-Based Biomarkers for Remote Monitoring of ALS Progression Across Languages	Robin		Jansen
Posteression A - Monday June 17, 17:30-18:30 hrs	24375	An Investigation of Methods and Anchors for estimating Clinically Important Differences in Multimodal Speech Biomarkers for Tracking Speech Impairment	Hardik		Kothare
Posteression A - Monday June 17, 17:30-18:30 hrs	24377	Decreased neurofilament levels upon tofersen treatment corroborate pathogenicity of the SOD1 p.D91A variant in ALS patients	Michael		Neumann
Posteression A - Monday June 17, 17:30-18:30 hrs	24400	CUTANEOUS SILENT PERIODS IN PATIENTS WITH EARLY-STAGE ALS	Jochen		Weishaupt
Posteression A - Monday June 17, 17:30-18:30 hrs	24402	Understanding neurofilament isoform biomarkers dynamic in ALS using cell models of the disease.	Joel		Gutiérrez
Posteression A - Monday June 17, 17:30-18:30 hrs	24404	Application of Electrical Engineering Methods to Defining and Illustrating Disease Progression in ALS	Kathryn		Knowles
Posteression A - Monday June 17, 17:30-18:30 hrs	24406	Development of a Sensitive Hand Function Measurement Tool for Monitoring Changes in Clinical Trials of ALS and Other Neuromuscular Disorders	Ian		Wynyard
Posteression A - Monday June 17, 17:30-18:30 hrs	24398	Predictors of psychosocial adjustment in patients with amyotrophic lateral sclerosis	Angela		Genge
Posteression A - Monday June 17, 17:30-18:30 hrs	24404	Personalised prediction model of an ALSFRS-R total score and subscore for patients with amyotrophic lateral sclerosis at an early stage	Luisa		Balz
Posteression A - Monday June 17, 17:30-18:30 hrs	24005	Lumbar polydiscopathy of ALS – diagnostic challenge: a case report	Jinghong		Zhang
Posteression A - Monday June 17, 17:30-18:30 hrs	24006	Metabolic syndrome in adult patients with S ₀ -spinal muscular atrophy	Zoran		Vukolevic
Posteression A - Monday June 17, 17:30-18:30 hrs	24009	Effects of tofersen treatment in patients with SOD1-ALS in a "real-world" setting – a multicenter experience from the German Early Access Program	Bogdan		Bjelica
Posteression A - Monday June 17, 17:30-18:30 hrs	24010	Clinical, patient-reported outcomes and neurofilament light-chain response to tofersen in SOD1-ALS: A multicenter observational study over 18 months	Maximilian		Wiesenfarth
Posteression A - Monday June 17, 17:30-18:30 hrs	24033	Does carer psychological inflexibility moderate the relationship between MND symptomatology and emotions associated with carer anticipatory grief?	Thomas		Meyer
Posteression A - Monday June 17, 17:30-18:30 hrs	24036	COGNITIVE IMPAIRMENT IN MOTOR NEURON DISEASE AND ITS RELATIONSHIP WITH DIFFERENT CONDITIONING PARAMETERS OF QUALITY OF LIFE IN PATIENTS AND CAREGIVER	Ana Paula		Trucco
Posteression A - Monday June 17, 17:30-18:30 hrs	24039	Rate of change in upper and lower motor neuron burden is associated with measures of survival in amyotrophic lateral sclerosis	Rosalía Yolanda		Morgado Linares
Posteression A - Monday June 17, 17:30-18:30 hrs	24040	Targeted proteome analysis of CSF and Serum identifies novel potential therapy-responsive biomarkers in SOD1-ALS upon treatment with Tofersen	Alessio		Maranzano
Posteression A - Monday June 17, 17:30-18:30 hrs	24042	Clinicopathological correlates in frontotemporal lobar degeneration – motor neuron disease spectrum	Christina		Steffke
Posteression A - Monday June 17, 17:30-18:30 hrs	24050	Cognitive performance and distress in the ALS clinic	Alvaro		Carbayo
Posteression A - Monday June 17, 17:30-18:30 hrs	24056	MULTIMODAL ASSESSMENT OF UPPER MOTOR NEURON INVOLVEMENT IN AMYOTROPHIC LATERAL SCLEROSIS	Colm		Peeto
Posteression A - Monday June 17, 17:30-18:30 hrs	24058	Assessment of cough deficiency, provision, and treatment with a mechanical insufflator-exsufflator in people with amyotrophic lateral sclerosis (ALS)	Francesca		Calvi
Posteression A - Monday June 17, 17:30-18:30 hrs	24072	Comparative analysis of different TBK1-ALS mutations in patient-derived motor neurons	Susanne		Spittel
Posteression A - Monday June 17, 17:30-18:30 hrs	24073	Making almost-locked-in people travelling and listening to concerts	Jahnavi		Srinidhi
Posteression A - Monday June 17, 17:30-18:30 hrs	24083	Bi-allelic ATXN2 repeat expansions cause autosomal, recessive ALS with slow progression and lower limb onset	Stefano		Sivoni
Posteression A - Monday June 17, 17:30-18:30 hrs	24088	Beliefs and attitudes towards medication and other interventions: a qualitative study of the lived experience of ALS patients and their caregivers	Koen		Demaegd
Posteression A - Monday June 17, 17:30-18:30 hrs	24089	Percutaneous endoscopic gastrostomy (PEG) in ALS – treatment satisfaction and medication administration practice	Alfaisal		Taymoor
Posteression A - Monday June 17, 17:30-18:30 hrs	24100	Time to intervention events in ALS disease journey: A German multicenter real-world cohort analysis	André		Maier
Posteression A - Monday June 17, 17:30-18:30 hrs	24101	Enhancing Treatment Adherence and Clinician Education: Addressing Formulation Changes in Amyotrophic Lateral Sclerosis Management	André		Maier
Posteression A - Monday June 17, 17:30-18:30 hrs	24107	The usage of population and disease registries as pre-screening tools for clinical trials, a systematic review	Federica		Cerri
Posteression A - Monday June 17, 17:30-18:30 hrs	24114	Validation of the 8-Item Somatic Symptom Scale (SSS-8) in Patients with Amyotrophic Lateral Sclerosis	Juliette		Foucher
Posteression A - Monday June 17, 17:30-18:30 hrs	24120	Classifying Patients with Amyotrophic Lateral Sclerosis by Disease Progression Rate	Federica		Cerri
Posteression A - Monday June 17, 17:30-18:30 hrs	24125	Understanding the impact of model misspecification in the combined analysis of longitudinal and survival data: a simulation study	Jinghong		Zhang
Posteression A - Monday June 17, 17:30-18:30 hrs	24126	A personalized prediction model of an ALSFRS-R total score and subscore for patients with amyotrophic lateral sclerosis at an early stage	Daphne		Weemering
Posteression A - Monday June 17, 17:30-18:30 hrs	24136	Event related potentials enable discrimination of cognitive network impairment occurring in ALS and MS	Jinghong		Zhang
Posteression A - Monday June 17, 17:30-18:30 hrs	24140	Prognostic Implications of Thoracic Denervation in Amyotrophic Lateral Sclerosis: A Retrospective Study	Eileen		Giglia
Posteression A - Monday June 17, 17:30-18:30 hrs	24149	What ALS wants?	Veria		Vacchiano
Posteression A - Monday June 17, 17:30-18:30 hrs	24155	Disrupting amyotrophic lateral sclerosis linked to NEX1 mutations	Eisabette		Pupillo
Posteression A - Monday June 17, 17:30-18:30 hrs	24156	Progression of cognitive impairment in ALS: preliminary findings from a longitudinal monocentric study in Italy	Anna		Ponomarenko
Posteression A - Monday June 17, 17:30-18:30 hrs	24169	A comparison of the German, Polish and Swedish versions of ECAS	Veronica		Bettoni
Posteression A - Monday June 17, 17:30-18:30 hrs	24176	Cervical lower motor neuron syndromes: a diagnostic challenge	ivar		Winroth
Posteression A - Monday June 17, 17:30-18:30 hrs	24178	Developing Multimodal Intelligent Methods for Orofacial and Speech Assessment to predict ALS bulbar decline	Gianni		Soraru
Posteression A - Monday June 17, 17:30-18:30 hrs	24187	A novel homozygous deletion of the OPTN gene leading to loss of protein expression in a case of typical ALS	Francesca		Bianchi
Posteression A - Monday June 17, 17:30-18:30 hrs	24196	Cognitive dysfunction in Amyotrophic Lateral Sclerosis: lexical decision-making as a possible biomarker? Prospective Longitudinal Clinic-based Patient Registry: Coordination, Data Quality, Compliance, Sustainability, and Sharing	Federica		Paredi
Posteression A - Monday June 17, 17:30-18:30 hrs	24197	Translating Aptamers to the Clinic – A Systematic Review and Meta-Analysis	LUCREZIA		BECATTINI
Posteression A - Monday June 17, 17:30-18:30 hrs	24210	How to detect emotion recognition alterations in Amyotrophic Lateral Sclerosis	Alexander		Sherman
Posteression A - Monday June 17, 17:30-18:30 hrs	24221	A common marker of emotion recognition dysfunction in the FTD spectrum of disorders	Alexander		Jackson
Posteression A - Monday June 17, 17:30-18:30 hrs	24224	Calculated maximal volume ventilation (cMVV) as a marker of early respiratory failure in Amyotrophic Lateral Sclerosis (ALS)	Veronica		Castelnovo
Posteression A - Monday June 17, 17:30-18:30 hrs	24230	Coping as a resource to allow for psychosocial adjustment in ALS: Results from ALS patients in the ALS/FTLD Registry Swabia	Elisa		Canu
Posteression A - Monday June 17, 17:30-18:30 hrs	24234	Utilising a machine learning-based audio-visual analysis of speech in patients with motor neuron diseases: A pilot study.	Enrico		Matteoni
Posteression A - Monday June 17, 17:30-18:30 hrs	24240	Early-Onset ALS: A Unique Disease Pattern	Dorothee		Lulé
Posteression A - Monday June 17, 17:30-18:30 hrs	24244	Regional Progression Interval: An Independent Prognostic Indicator of Faster Disease Progression in Amyotrophic Lateral Sclerosis	Ricarda		von Heynitz
Posteression A - Monday June 17, 17:30-18:30 hrs	24249	Cardio-metabolic conditions in relation to ALS risk and progression – a longitudinal study	Krzysztof		Barc
Posteression A - Monday June 17, 17:30-18:30 hrs	24250	Interhemispheric M1 functional connectivity increases longitudinally in ALS during execution of motor task	Krzysztof		Barc
Posteression A - Monday June 17, 17:30-18:30 hrs	24252	Preliminary results	Charilaos		Chourpiliadis
Posteression A - Monday June 17, 17:30-18:30 hrs	24255	Two Monozygotic Twins Discordant for ALS Disease	Saroj		Bista
Posteression A - Monday June 17, 17:30-18:30 hrs	24264	PRACTICAL APPLICATION OF MULTI-MUSCLE ELECTROPHYSIOLOGY IN CLINICAL TRIALS	Abir		Alaamet
Posteression A - Monday June 17, 17:30-18:30 hrs	24266	Supporting home physiotherapists by training and implementing validated assessments for ALS patients	Dierik		Stilvoort
Posteression A - Monday June 17, 17:30-18:30 hrs	24269	Acoustic Measures of Voice Quality from a Picture Description Task Correlate with ALS Subscore Severity	Maj-Britt		Bartels
Posteression A - Monday June 17, 17:30-18:30 hrs	24275	The role of independent patient guides in coordinating ALS care in a mixed rural and urban population in northwest Germany	Andreas		Hermann
Posteression A - Monday June 17, 17:30-18:30 hrs	24277	Long-term treatment of SOD1 ALS with tofersen: a multicentre experience in 17 patients.	Hanna		Stüber
Posteression A - Monday June 17, 17:30-18:30 hrs	24280	A promising decision tool for Tofersen treatment in FTCD SOD1 mutations, based on protein 3D Modeling: a case study on the p.Ser108Leu/ser115 mutation.	Marlo		Sabatelli
Posteression A - Monday June 17, 17:30-18:30 hrs	24284	ALSFRS-R Subscore progression is phenotype specific and stable through disease accumulation in ALS patients	Christian		Lunetta
Posteression A - Monday June 17, 17:30-18:30 hrs	24287	UNC13A polymorphism shortens survival in behavioural variant frontotemporal dementia	Behnaz		Farahigharabonassar
Posteression A - Monday June 17, 17:30-18:30 hrs	24288		Sean		Willemsse

	NX210c for recovering Blood Brain Barrier integrity in ALS patients: In silico modelling framework for dose selection and design of a phase II study.	Annette Benedetta Monica	Janus Tafuri Consommi
Poster session A - Monday June 17, 17:30-18:30 hrs	24289 Radiomics alterations of hypothalamic nuclei and relationship with BMI in ALS		
Poster session A - Monday June 17, 17:30-18:30 hrs	24306 Social lifetime functioning as a protective factor, like cognitive reserve, against neurodegeneration in ALS		
Poster session A - Monday June 17, 17:30-18:30 hrs	The EU ALS Coalition call for action: Roadmap of the policy changes needed across Europe to improve the lives of PALS across their careers across Europe	Evy	Reviere
Poster session A - Monday June 17, 17:30-18:30 hrs	TARDP mutation in a Southern Italy family affected by FALS: development of a targeted biological samples collection.	Antonio	Fasano
Poster session A - Monday June 17, 17:30-18:30 hrs	24311 Description of Patient Report Outcomes of Treatments used for Amyotrophic Lateral Sclerosis	Alex	Berger
Poster session A - Monday June 17, 17:30-18:30 hrs	24313 A clinical scale for rating the severity of bulbar lower motor neuron dysfunction in Amyotrophic Lateral Sclerosis.	Alessia	Giugno
Poster session A - Monday June 17, 17:30-18:30 hrs	24316 Mechanism regulating the expression of the fragile X protein family in ALS and other neurodegenerative diseases: A retrospective analysis of a group of patients diagnosed with Amyotrophic Lateral Sclerosis from the University of Pisa	Lorena	Decker
Poster session A - Monday June 17, 17:30-18:30 hrs	24326 Ecological validity of performance-based cognitive screeners in amyotrophic lateral sclerosis: preliminary evidence	Caterina	Meoni
Poster session A - Monday June 17, 17:30-18:30 hrs	24343 Treatment Benefits Reported by People Living with ALS/MND in the PatientLikeMe Platform	Edoardo Nicolò Ian Barbara	Aiello Wymyard Poletti
Poster session A - Monday June 17, 17:30-18:30 hrs	24352 Unraveling the contribution of executive functions to language impairment in ALS: The impact of the rehabilitation medical specialist in a multidisciplinary in-hospital consultation of patients affected by motor neuron diseases	Pablo	Peret Hernández
Poster session A - Monday June 17, 17:30-18:30 hrs	24358 Clinical and Genetic Features of Patients with Amyotrophic Lateral Sclerosis in Turkey: Data From a Single Center	Gulshan	Yunisova
Poster session A - Monday June 17, 17:30-18:30 hrs	24360 Dutch norm data of PROMIS-10 Global Health	Ann Katrin	Schmidt
Poster session A - Monday June 17, 17:30-18:30 hrs	24362 Illness denial in a cohort of ALS patients and caregivers	Lucia	Grieco
Poster session A - Monday June 17, 17:30-18:30 hrs	24366 Speech markers distinguishing dysarthria in Motor Neuron diseases (MND)	Nathalie	Lévesque
Poster session A - Monday June 17, 17:30-18:30 hrs	24372 Chest MRI to assess respiratory involvement in ALS patients	Alessandro	Bombaci
Poster session A - Monday June 17, 17:30-18:30 hrs	24378 Cognitive impairment and decision-making capacity in ALS: Implications for clinical trial recruitment	Debbie	Gray
Poster session A - Monday June 17, 17:30-18:30 hrs	24381 Exploring personality, psychological stress, resilience, and coping in ALS	Lisa	Kraneburg
Poster session A - Monday June 17, 17:30-18:30 hrs	24391 Real-World Evaluation of the Rasch-built Overall ALS Disability Scale (ROADS) and the Self-Evaluated ALSFRS-R Through Telemedicine	Alejandro	Caravaca Puchades
Poster session A - Monday June 17, 17:30-18:30 hrs	24394 Development of a complex intervention model for end of life care in patients with amyotrophic lateral sclerosis. THE CLINICAL COURSE OF THE SWALLOWING AND SPEECH PROBLEMS IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS	Fouke	Ombelet
Poster session A - Monday June 17, 17:30-18:30 hrs	24395 Measuring health-related quality of life in motor neuron disease: systematic review, conceptual framework and PROM development	Eva	Vlčková
Poster session A - Monday June 17, 17:30-18:30 hrs	24396 Neurofilaments as Biomarkers in the Differential Diagnosis of Amyotrophic Lateral Sclerosis and Multifocal Motor Neuropathy	Christopher	McDermott
Poster session A - Monday June 17, 17:30-18:30 hrs	24037 The pattern of paresis in ALS - clinical and MRI studies.	Camilla	Wohnrade
Poster session A - Monday June 17, 17:30-18:30 hrs	24075 Immune cells and psychiatric and cognitive outcomes in ALS patients	Albert	Ludolph
Poster session A - Monday June 17, 17:30-18:30 hrs	24097 Integrated miRNA approaches for ALS diagnosis and therapeutic targeting	Yihan	Hu
Poster session A - Monday June 17, 17:30-18:30 hrs	24157 IMPACT OF SOCIOECONOMIC STATUS ON THE SURVIVAL OF ALS PATIENTS	Mafalda Juan Francisco	Rizzuti Vazquez Costa
Poster session A - Monday June 17, 17:30-18:30 hrs	24166 T1-weighted MRI texture analyses in Amyotrophic Lateral Sclerosis patients stratified by the D50 disease progression model	Karin	Forsberg
Poster session A - Monday June 17, 17:30-18:30 hrs	24208 Disentangling brain functional neural organization of apathy and depression in ALS: a connectome-based approach	Robert	Steinbach
Poster session A - Monday June 17, 17:30-18:30 hrs	24213 Parietal GABA levels in asymptomatic C9orf72 mutation carriers and ALS patients studied using magnetic resonance spectroscopy at 7T	Veronica	Castelnovo
Poster session A - Monday June 17, 17:30-18:30 hrs	24002 Do we need a Phase 0 in ALS trials?	Wytse	van Hoek
Poster session A - Monday June 17, 17:30-18:30 hrs	24011 Long-term Survival of Participants in a Phase II Trial of RNS60 in Amyotrophic Lateral Sclerosis	Joachim	Schuster
Poster session A - Monday June 17, 17:30-18:30 hrs	24014 Ketogenic diet - a potential treatment option in ALS? Effect of Oral Rho-Kinase Inhibitor Fasudil on Neurofilament Light Chain: An open-label phase 2a study to assess safety, tolerability and efficacy of the rho kinase inhibitor fasudil in ALS (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial	Christine	Herrmann
Poster session A - Monday June 17, 17:30-18:30 hrs	24021 Safety, tolerability and efficacy of the rho kinase inhibitor fasudil in ALS (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial	Ruben	van Eijk
Poster session A - Monday June 17, 17:30-18:30 hrs	24106 Trial quality in disease-modifying ALS trials: a systematic review	Paul	Lingor
Poster session A - Monday June 17, 17:30-18:30 hrs	24127 A proof of concept study of the PI3K inhibitor VEG005 in patients with sporadic and familial ALS	Floris	van Loon
Poster session A - Monday June 17, 17:30-18:30 hrs	24131 CardINALS: a phase 2, randomized, double-blind, placebo-controlled study of utrogestat (PTC857) in patients with amyotrophic lateral sclerosis	Diego	Cadavid
Poster session A - Monday June 17, 17:30-18:30 hrs	24132 EPISOD: A Phase 1/2, Multicenter Study to Evaluate Safety, Tolerability & Exploratory Efficacy of Intrathecal Gene Therapy AMT-162 in SOD1-ALS Pts.	Jeremy	Sheffer
Poster session A - Monday June 17, 17:30-18:30 hrs	24134 Interim Analysis of the Radicava/Edaravone Findings in Biomarkers from ALS (REFINE-ALS) Study	Dr Arshia	Almad
Poster session A - Monday June 17, 17:30-18:30 hrs	24142 Phase 3, Open-Label, Safety Extension Study of Oral Edaravone Administered Over 96 Weeks in Patients with ALS (MT-1186-403)	Martina	de Majo
Poster session A - Monday June 17, 17:30-18:30 hrs	24143 Treatment Patterns and Survival Benefit of Edaravone-Treated People With Amyotrophic Lateral Sclerosis in the ALS/MND Natural History Consortium	Stephen	Apple
Poster session A - Monday June 17, 17:30-18:30 hrs	24167 Safety, tolerability and gut microbiota analysis of an oral microbiotherapy in amyotrophic lateral sclerosis: an open-label phase 1b pilot trial-IASO	Stephen	Apple
Poster session A - Monday June 17, 17:30-18:30 hrs	24190 Using Historical Control Data in Early-Stage Exploratory Efficacy Analysis of Monepantel in ALS	Adèle	Hesters
Poster session A - Monday June 17, 17:30-18:30 hrs	24195 Efficacy and Safety of SAR443820 (RIPK1 Inhibitor) in Adults with ALS: Results from the HIMALAYA Trial	Philip	White
Poster session A - Monday June 17, 17:30-18:30 hrs	24201 Critical considerations for the design of interim analysis in clinical trials for amyotrophic lateral sclerosis	Merit	Cudkowicz
Poster session A - Monday June 17, 17:30-18:30 hrs	24225 Systematic Review and Meta-Analysis of Treatment Discontinuation Rates in Amyotrophic Lateral Sclerosis Clinical Trials	Francesca	Calligaris
Poster session A - Monday June 17, 17:30-18:30 hrs	24257 PrimeC, An Oral Candidate for Amyotrophic Lateral Sclerosis, Meets Primary Safety and Secondary End Points in the Phase 2b PARADIGM Trial	Jordi	van Ulmrik
Poster session A - Monday June 17, 17:30-18:30 hrs	24273 PRO-101: Study design and interim results from a hybrid first-in-human study to evaluate the safety and pharmacokinetics of prosetin in ALS	Ruben	van Eijk
Poster session A - Monday June 17, 17:30-18:30 hrs	24281 Efficacy and safety evaluation of Tofersen treatment in patients with SOD1-ALS	Erin	Fleming
Poster session A - Monday June 17, 17:30-18:30 hrs	24300 Evaluating the Impact of Acetyl-L-Carnitine on Survival in ALS Patients: A Retrospective Cohort Study	Pilar Helena Emanuele	García Casanova Koumantakis
Poster session A - Monday June 17, 17:30-18:30 hrs	24301 Reduction of Neurofilament Light (NFL) Levels and Improved Survival in ALS with CNM-Au8 Treatment, Results from HEALEY ALS Platform Regimen C QLE	Marjan	Sepassi
Poster session A - Monday June 17, 17:30-18:30 hrs	24307 Development of a remote, patient-centric, clinical trial model using digital healthcare technology	Lianne	Botman
Poster session A - Monday June 17, 17:30-18:30 hrs	24340 Pridopidine For the Treatment of ALS - Results From the Phase 2 Healey ALS Platform Trial	Michal	Geva
Poster session A - Monday June 17, 17:30-18:30 hrs	24389 Statistical Innovation and Complexities in the HEALEY ALS Platform Trial: Lessons Learned From the First Set of Regimens	Melanie	Quintana
Poster session A - Monday June 17, 17:30-18:30 hrs	24001 Head injury and amyotrophic lateral sclerosis: a population-based study from the National ALS Registry, 2015-2023	Paul	Mehta
Poster session A - Monday June 17, 17:30-18:30 hrs	24137 Preliminary Analysis of Treatment Patterns in Patients With Amyotrophic Lateral Sclerosis Using Electronic Health Records	Malgorzata	Ciepielewka
Poster session A - Monday June 17, 17:30-18:30 hrs	24207 Physical activity in relation to risk of ALS in the UK Biobank cohort	Jiali	Gao
Poster session A - Monday June 17, 17:30-18:30 hrs	24255 Proton pump inhibitors and amyotrophic lateral sclerosis: A case-control study	Inde	Aves
Poster session A - Monday June 17, 17:30-18:30 hrs	24305 Epidemiology of Amyotrophic Lateral Sclerosis in Catalonia (Spain): 2015-2023	Sergio	Vidal Notari
Poster session A - Monday June 17, 17:30-18:30 hrs	24305 A population-based disease mapping of ALS incidence in the Republic of Ireland from 1995 to 2022	Éanna	Mac Donnhail
Poster session A - Monday June 17, 17:30-18:30 hrs	24324 Diagnostic trajectory and delays in ALS patients during the COVID-19 pandemic: A comparative analysis of pre-pandemic and pandemic cohorts	Silvia	Pérez Albertos
Poster session A - Monday June 17, 17:30-18:30 hrs	24338 The ALSMOND population based registry for Neuromuscular and Motoneuron diseases in Northwest Germany: The Hanse experience	Kristin	Loyal
Poster session A - Monday June 17, 17:30-18:30 hrs	24128 The natural history of frontotemporal lobe degeneration and its association with amyotrophic lateral sclerosis in the ALS/FTLD Registry Swabia	Angela	Rosenbohm
Poster session A - Monday June 17, 17:30-18:30 hrs	24387 Retrospective Study of the Natural History of ALS in the PARALS and ERRALS Registries in Italy	Katie	Stenson
Poster session A - Monday June 17, 17:30-18:30 hrs	24295 Amyotrophic lateral sclerosis caused by the C9orf72 expansion in Norway - prevalence, aetiology, clinical and demographic variables	Helle	Hoyer
Poster session A - Monday June 17, 17:30-18:30 hrs	24331 Revisiting ALS in Turkey: The Molecular Landscape of a Complex Disorder	Elif	Bayraktar
Poster session A - Monday June 17, 17:30-18:30 hrs	24393 Genetic landscape of amyotrophic lateral sclerosis in Czechia and Slovakia	Lenka	Slachťova
Poster session A - Monday June 17, 17:30-18:30 hrs	24214 Longitudinal progression of subcortical structural damage in amyotrophic lateral sclerosis	Edoardo Gioele	Spinelli
Poster session A - Monday June 17, 17:30-18:30 hrs	24317 Regional vulnerability of the connectome topology in ALS	Boaz	Kalkhoven
Poster session A - Monday June 17, 17:30-18:30 hrs	24370 Precentral cortical thickness corrected for attrition bias shows potential as a longitudinal brain imaging biomarker in Amyotrophic Lateral Sclerosis	Maria Janina	Wendebourg
Poster session A - Monday June 17, 17:30-18:30 hrs	24179 Mild Motor Impairment as a Prodromal State and a Risk Factor for Phenocopy Conversion to Clinically Manifest ALS	Michael	Benatar
Poster session A - Monday June 17, 17:30-18:30 hrs	24350 Resting-state beta-band EEG alterations in asymptomatic C9orf72 repeat expansion carriers	Stefan	Dukic
Poster session A - Monday June 17, 17:30-18:30 hrs	24373 How does strenuous exercise affect disease penetrance in people carrying C9orf72 and SOD1 mutations associated with ALS?	David	O'Brien
Poster session A - Monday June 17, 17:30-18:30 hrs	24380 Association between early-life and prembiotic measurements of body composition and risk of ALS: a prospective cohort study in the UK Biobank	Emily	Joyce
Poster session A - Monday June 17, 17:30-18:30 hrs	24397 FDG-PET clustering analysis in Amyotrophic Lateral Sclerosis	Joke	De Vocht
Poster session A - Monday June 17, 17:30-18:30 hrs	24013 Targeting the energy deficit in ALS - the LIPCAL-ALS II study	Johannes	Dorst
Poster session A - Monday June 17, 17:30-18:30 hrs	24262 Rare variants in the genetic background modulate risk and phenotype in ALS	Maurizio	Grassano
Poster session A - Monday June 17, 17:30-18:30 hrs	24024 Cognitive Deficits in ALS patients with SOD1 mutations	Ivar	Winroth
Poster session A - Monday June 17, 17:30-18:30 hrs	24079 Physical activity, fitness and long-term risk of amyotrophic lateral sclerosis - a prospective cohort study	Anders Myhre	Vaage
Poster session A - Monday June 17, 17:30-18:30 hrs	24335 Exploring the Genetic Underpinnings of Cognition in ALS through Multi-Trait GWAS Analysis	Emrah	Kacar
Poster session A - Monday June 17, 17:30-18:30 hrs	24253 Longitudinal cognitive assessment using the Cumulus home-based EEG platform in ALS and FTD.	Emmet	Costello
Poster session A - Monday June 17, 17:30-18:30 hrs	24312 Defining functional brain network changes in ALS at higher temporal resolution	Alicia	Northall
Poster session A - Monday June 17, 17:30-18:30 hrs	24384 Associations between resting-state electroencephalographic (EEG) measures and cognitive functions in ALS: a preliminary region-specific analysis	Serena	Paltano
Poster session A - Monday June 17, 17:30-18:30 hrs	24333 Association study on HERV-K genomic insertions in Amyotrophic Lateral Sclerosis	Simon	Topp
Poster session A - Monday June 17, 17:30-18:30 hrs	24023 Is a brief apathy assessment useful in motor neuron disease clinics?	Ratko	Radkovic

Posteression A - Monday June 17, 17:30-18:30 hrs	24109 Investigating the potential of apathy as a predictor for ALS trial-participation.	Juliette	Foucher
Posteression A - Monday June 17, 17:30-18:30 hrs	Education mediates the association between motor and cognitive-behavioural features in non-demented ALS		
Posteression A - Monday June 17, 17:30-18:30 hrs	24369 patients	Edoardo Nicodò	Aiello
Posteression A - Monday June 17, 17:30-18:30 hrs	24267 An update on the role of autoantibodies against neurofilaments in amyotrophic lateral sclerosis (ALS)	Ellie	Sturmyer
Posteression A - Monday June 17, 17:30-18:30 hrs	24048 Intelligence Integration		
Posteression A - Monday June 17, 17:30-18:30 hrs	BRAINTEASER Project: Enhancing Amyotrophic Lateral Sclerosis Care through Remote Monitoring and Artificial Intelligence Integration	Inês	Aves
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24181 Deregulation of neurofilaments in ATXN-2-ALS motor neurons cause endo-lysosomal trafficking defects	Katja	Burk
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24003 Understanding the role of strenuous exercise in potentiating MND in Drosophila melanogaster	Debarati	Bhattacharya
Posteression B - Tuesday June 18, 17:45-18:45 hrs	Elucidating key drivers of RNA dysregulation in ALS using a novel model of TDP43 proteinopathy and ePRINT technology	Akhay	Bhingé
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24015 technology	Farah	Mahidine
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24017 Methylation and One-Carbon Metabolism in TDP-43 Proteinopathies		
Posteression B - Tuesday June 18, 17:45-18:45 hrs	A deep learning model of rare non-coding regulatory genetic variation within motor neurons reveals CCDC146 as a modulator of ALS survival	Johnathan	Cooper-Knock
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24022 Dipeptide-repeat proteins cause cytoskeletal disorganization in C9orf72-MND	Charlotte	Gale
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24030 Inhibitory synapses in ALS: dysfunction and response to Chemogenetic and intrabody modulation	Kareem	Halabiab
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24051 Aberrant Splicing in Neurodegeneration Beyond TDP-43	Thea	Meimoun
Posteression B - Tuesday June 18, 17:45-18:45 hrs	MORPHOGEN-INDUCED DIFFERENTIATION OF STEM CELLS INTO OCULOMOTOR NEURONS TO MODEL RESILIENCE IN AMYOTROPHIC LATERAL SCLEROSIS	Silvia	Gómez
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24061 Nuclear PPIA redistribution and increased PPIA acetylation in FBMCS of ALS patients: a possible compensatory mechanism preventing TDP-43 aggregation	Valentina	Bonetto
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24066 Cellular Defects Induced by the Loss of Fragile X-Proteins in Neurodegenerative Diseases	Sonja	Menge
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24080 Intracellular distribution of FUSp-Y526 in ALS	Helena	Motalin
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24084 Discovering molecular dynamics of fibroblast activation in amyotrophic lateral sclerosis	Yigit Koray	Babal
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24103 Impact of irreversible cytoplasmic localization on the TDP-43 interactome	Jerneja	Nimac
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24108 Stress-induced TDP-43 nuclear condensation causes loss of function in splicing and STMN2 depletion	WAN-PING	HUANG
Posteression B - Tuesday June 18, 17:45-18:45 hrs	Hypothesis-free Mendelian Randomisation Identifies New Metabolites and Athletic Metabolites Linked to Risk of ALS	Etham	Alhathil
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24117 Exploring spinal cord ependymal stem progenitor cells' metabolic profile to develop a new therapeutic approach to rescue neurodegeneration in ALS.	Marco	Cattaneo
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24124 Restoring ATG4B expression in ALS models normalize autophagy and LC3ylation	Pascual	Torres
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24129 VCP191Q+/- induces opening of the mitochondrial permeability transition pore	Silke	Vanderhaeghe
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24141 Ultrastructural changes on the surface of astrocytes induced by ALS IgG	Pavle	Andjus
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24144 Transcriptomic Signature Induced by Edaravone in Motor Neurons From an ALS Patient With a TDP-43 Mutation	Makoto	Tamura
Posteression B - Tuesday June 18, 17:45-18:45 hrs	Novel strategies to facilitate non-homologous end-joining (NHEJ) repair and prevent DNA damage in Amyotrophic Lateral Sclerosis (ALS)	Sina	Shadfar
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24149 Metabolic transformation in cellular and animal life models	Whujana	Ningaj
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24150 Oxidative stress and metabolic profiles and its influence on functionality in ALS patients from Spain	Belen	Praho
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24151 Isoelectric point shift in aberrant C-terminal domain leads to aggregation of ALS mutated KIF5A and TDP43 mislocalization	Pietro	Zanella
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24153 Molecular signatures of TDP-43 dysfunction are time dependent, variable, and therapeutically targetable in ALS	Alyssa	Coyne
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24173 Transcriptome-wide RNA binding analysis of C9orf72 poly(PR) dipeptides	Rubika	Balendra
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24174 Assessment of the impact of cyanotoxin L-BMAA on α -Synuclein and TDP43 proteinopathy	Claudia	Crosio
Posteression B - Tuesday June 18, 17:45-18:45 hrs	Pharmacological mGlu5 receptor modulation hampers aberrant activation and neurotoxicity of human ALS astrocytes: perspective for clinical application	Marcello	Milanese
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24176 Uncovering the transcriptomic architecture of the motor cortex in ALS and its extreme motor phenotypes	Isabelle	Cordts
Posteression B - Tuesday June 18, 17:45-18:45 hrs	Edaravone ameliorates the enhanced glutamatergic transmission onto motor neurons in the spinal cord of a mouse model of Amyotrophic Lateral Sclerosis.	Yun Kyung	Park
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24210 The thymus in the pathogenesis/pathophysiology of Amyotrophic Lateral Sclerosis	Julia	P. Lemos
Posteression B - Tuesday June 18, 17:45-18:45 hrs	TROPICITY AND TOXICITY OF MACROPHAGES AND MICROGLIA TOWARDS MOTOR NEURONS IN AMYOTROPHIC LATERAL SCLEROSIS	Delphine	Bohl
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24216 AMYOTROPHIC LATERAL SCLEROSIS		
Posteression B - Tuesday June 18, 17:45-18:45 hrs	CYTOPLASMIC AGGREGATION OF WT TDP-43 AND FUS P525L CAUSES GENOME DAMAGE IN A CELLULAR MODEL SYSTEM OF ALS	Stefania	Modafferi
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24227 Exploring the Lipid Jungle of ALS: TDP-43 Expedition	Anna	Fernández Bernal
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24229 Sex-specific DNA methylation differences in Amyotrophic lateral sclerosis	OLIVIA	GRANT
Posteression B - Tuesday June 18, 17:45-18:45 hrs	A novel humanised zebrafish model of TDP-43 pathology exhibits early neuronal and glial dysfunction, relevant for phenotypic drug discovery.	Marcus	Keatings
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24232 Understanding the relationship between dyslipidaemia and TDP-43 aggregation	Tatiana	Langerova
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24236 Elucidating Mechanisms Underpinning Impaired Hypoxia Response Pathways in C9orf72-related MND	Ergta	Balli
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24238 TDP-43 pathology in a novel cohort of individuals with altered bowel habit	Tatiana	Langerova
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24239 PARP dependent cell death pathway in SOD1, TDP-43 and C9orf72 models of familial ALS	Yuyal	Avni Mann
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24241 The impact of metabolic alteration on synaptic failure in Amyotrophic Lateral Sclerosis	Amr	Aly
Posteression B - Tuesday June 18, 17:45-18:45 hrs	Impaired Translation of UNC13A and PURA in Motor Neurons with C9orf72 Mutations During Recovery from Acute Oxidative Stress	Yinyan	Xu
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24256 Targeting Upper Motor Neurons: A Cutting-Edge Neural Stem Cell Therapy for Amyotrophic Lateral Sclerosis	Luca	Sali
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24265 Targeting SPT1 in ALS neurodegeneration	Jianning	Lin
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24272 Understanding the role of astrocytes in C9orf72-mediated ALS/FTSD: a systematic review and meta-analysis	Stella	Taso
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24274 Deciphering Novel Glial Differential Markers in Amyotrophic Lateral Sclerosis	Sara	Marmolejo Martinez-Artesero
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24276 IRON METABOLISM-GENETIC INTERPLAY IN AN ALS COHORT: A SINGLE-CENTER STUDY	Barbara	Risi
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24279 Paraspeckle dysregulation: a common disease mechanism among diverse forms of ALS?	Tresa	López-Royo
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24283 Long intracortical inhibition is not abnormal in ALS – A threshold tracking TMS study	Roisin	McMackin
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24292 Auto-reactive T cells in Amyotrophic lateral sclerosis	Elie	Deeba
Posteression B - Tuesday June 18, 17:45-18:45 hrs	The role of tubulin post-translational modifications in the therapeutic effect of HDAC6 inhibition in amyotrophic lateral sclerosis.	Dulfe	Strubbe
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24302 Mislocalization of TDP-43 in brains of ALS and FTD patients	Laura	Expósito Blázquez
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24304 Modeling a novel N-terminal mutation of KIF5A gene in patient-derived iPSC-motoneurons	Sabrina	Invernizzi
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24345 Optical Genome Mapping versus Southern blot for C9orf72 repeat expansion sizing	Silvia	Peverelli
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24347 Investigation of ALS-related motor neuron pathology in hiPSC-derived cortical neurons	Eli	Bayraktar
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24349 Targeting aberrant intron retention in motor neurone disease	Yiran	Wang
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24363 Interrogating the differential toxicity of C9orf72 astrocytes against ALS motor neurons and FTD cortical neurons	Monika	Myszczynska
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24367 Investigating the Role of Cryptic Exons in Amyotrophic Lateral Sclerosis	John	Jammal
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24371 Exploring the mechanistic disease biology of Amyotrophic Lateral Sclerosis in patient transcriptomics datasets	ALESSANDRA	CARDINALI
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24374 Molecular factors that implicate involvement of ORF1p from LINE1 in ALS	Klementina	Polanc
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24376 offers new biomarker potential	Marcel	Naumann
Posteression B - Tuesday June 18, 17:45-18:45 hrs	A pilot study to investigate Exosomes and Human Endogenous Retroviruses (HERVs) as biomarkers in Motor Neuron Disease (MND)	Triparna	Roy
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24399 Probing astroglial dysfunction and its associated molecular mechanisms in ALS transgenic mice	XiaoQian	Ye
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24218 Developing automated assays to study iPSC-derived motor neurons from ALS patients	Elena	Pasho
Posteression B - Tuesday June 18, 17:45-18:45 hrs	Combining aptamers and human tissue microarrays to advance research at scale in ALS: TDP-43APT reveals novel neuropathological features of C9orf72-ALS	Jenna	Gregory
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24016 Heterozygous knockout of SYT13 in human motor neurons phenocopies ALS	Alberto	Catanesse
Posteression B - Tuesday June 18, 17:45-18:45 hrs	Investigating TDP43 loss of function in neuromuscular junction denervation by using a human stem cell derived neuromuscular assembloid model	Andrea	Salzinger
Posteression B - Tuesday June 18, 17:45-18:45 hrs	The beneficial impact of moderate physical exercise on the neuromuscular system of ALS mice: Functional, histologic and biochemical insights	Laila	Just-Borrás
Posteression B - Tuesday June 18, 17:45-18:45 hrs	miR29 mediates extracellular muscle protection in zebrafish models of muscular dystrophies and its ectopic expression ameliorates affected neuromuscular	Nils	Demnag
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24076 Impact of Naringenin on primary microglial cells and motor neurons derived from mutant SOD1-G93A mice	Thomas	Gschwendtberger
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24118 Molecular and functional characterization of hiPSC-derived skeletal muscle carrying a TDP-43 mutation	Domino	Schlegel
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24152 Pharmacological and genetic modifiers of ALS-associated phenotypes in Drosophila melanogaster	Hrvoje	Augustin
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24162 A longitudinal, biological, and phenotypic evaluation of A315T TDP-43 transgenic mice	Samira	Osman
Posteression B - Tuesday June 18, 17:45-18:45 hrs	Single nuclei RNA-Sequencing analysis in the spinal cord and motor cortex of knock-in mice carrying a KIF5A ALS172 causative Δ exon27 mutation.	Rosanna	Parlato
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24226 Mutations in FUS cause synaptic dysregulation mediated by FMRP in induced pluripotent stem cells	Agnes	Nishimura
Posteression B - Tuesday June 18, 17:45-18:45 hrs	Early impairment of hypothalamic MCH neuronal network precedes disease onset and MCH degeneration in ALS mouse model	Jelena	Seckic-Zahirovic
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24237 Exploring the interplay between age and genotype in TBK1 p.E696K mice using snRNA-seq data	Sayed Babak	Loghmani
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24254 Musclin restrains muscle atrophy and NMJ degeneration in mouse models of ALS	Andrea David	Ra Ceccconi
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24263 Modelling the human neuromuscular junction in vitro	Irene	Mei
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24270 Characterisation of the role of iPSC-derived microglia with TARDBP mutations in ALS	Lara	Nikel
Posteression B - Tuesday June 18, 17:45-18:45 hrs	High Throughput Screening of an FDA-Approved Drug Library Using a TDP-43 Knockdown Cellular Model to Simulate Functional Loss	Marta	Santacreu-Vilaseca
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24293 Characterization of human i3 motor neurons exposed to CSF from ALS patients stratified by C9ORF72 and UNC13A genotype	Valeria	Casiraghi
Posteression B - Tuesday June 18, 17:45-18:45 hrs	Inhibition of the ISR kinase GCN2 delays disease onset and progression in the ALS transgenic mouse model SOD1G93A.	Montserrat	Arrasate
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24329 Elucidating the timing of TDP-43 related phenotypes using iPSC-derived motor neurons from TARDBP ALS patients	Melissa	Nijls
Posteression B - Tuesday June 18, 17:45-18:45 hrs	Characterizing Phenotypic Variability in Two ALS Mouse Models Through Automated Activity Monitoring and Plasma Light Neurofilaments Biomarker Analysis	Laura	Camporeale
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24364 ASC-extracellular vesicles as a therapeutic approach for neuroprotection in SOD1(G93A) mouse model of ALS	Federica	Virla
Posteression B - Tuesday June 18, 17:45-18:45 hrs	Profiling the motor neuron transcriptome and transcriptome across pre-symptomatic and early symptomatic stages of a TDP-43 mouse model of ALS.	Hannah	Smith
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24379 Nanopore sequencing of an inducible silencing TARDBP cellular model reveals potentially novel pathogenic pathways	Santiago	Rico Rios
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24008 Targeting TDP-43 with a full-length antibody mitigates pathology induced by infusion of CSF from ALS patients in mice.	Anklie	Poulin-Brière
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24025 Stably and enhanced AAV-mediated expression of the mitochondrial porin VDAC1 rescues the cellular energetic in a ALS1 mice model	Andrea	Magli

Posteression B - Tuesday June 18, 17:45-18:45 hrs	24029 Enoxacin, an enhancer of miRNA biogenesis, as a novel therapeutic strategy for ALS	Iddo	Magen
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24077 Therapeutic potential of Naringenin in the SOD1-G93A mouse model of Amyotrophic Lateral Sclerosis	Nadine	Thau-Habermann
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24092 ATH-1105, a small molecule targeting the neurotrophic HGF system, is neuroprotective and prolongs survival in the Prp-TDP43(A315T) mouse model of ALS	Andree-Anne	Berthiaume
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24093 Theapeutic effects of HLX99 on gut-brain axis for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases	Yong-giang	Shan
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24116 Targeting the sense and antisense pathogenic C9orf72 transcripts as therapy for C9orf72 ALS	Ying-Pei	Liu
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24122 Updates on Development of AMX0114: An Antisense Oligonucleotide Inhibitor of Calpain-2, a Critical Effector of Axonal Degeneration	Lauren	Kett
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24175 Characterization of a therapeutic approach to target TDP-43 proteinopathy using phage display-derived scv	Yara	Al Ojaimi
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24192 Development of a highly selective CNS-penetrant small molecule HDAC6 inhibitor for the treatment of ALS	Tonya	Gilbert
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24193 Development of a novel CNS-penetrant HDAC6 PET tracer for measuring in vivo target engagement	Tonya	Gilbert
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24199 Targeting low levels of MIF expression as a potential therapeutic strategy for ALS	Adrian	Israelson
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24200 IFB-088, a neuroprotective drug in mutated TDP-43 transgenic zebrafish	Emmanuelle	Abgueuen
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24248 Investigating Mechanisms of Neuroprotection from Therapeutic Targeting of Glycolysis	Helena	Chaytow
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24268 Exploiting Knowledge Graph-based Methods for Drug Repurposing in Amyotrophic Lateral Sclerosis	Anqi	Jiang
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24299 preclinical models of ALS	Jewel	Johnston
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24318 Pharmaceutical Landscape in ALS: industry perspective	Famke	Cosjin
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24319 Suppression of RNA splicing factors, SYF2, as a therapeutic strategy to address familial and sporadic ALS	Wen-Hsuan	Chang
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24322 Addressing iPSC derived motor neuron variability to improve model reproducibility for Motor Neuron Disease	Finbar	Gaffey
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24322 (MND) therapeutic discovery	Finbar	Gaffey
Posteression B - Tuesday June 18, 17:45-18:45 hrs	A Phase 2 Study to Assess the Safety, Tolerability, and Pharmacology of 15 mg of Darifenacin Daily in Patients With Amyotrophic Lateral Sclerosis	Nisha	Pulimood
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24334 Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of ARGX-119 in Patients with ALS: A Phase 2a Conceptual Study Design (nALS2)	Nisha	Pulimood
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24351 A 3D human motor neuron disease platform for high throughput drug screening	Alessia	Nicotra
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24403 Frequency of SOD1, FUS and TARDBP mutations in a multicenter screening program in Germany	Katharina	Hemml
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24031 Small striatal huntingtin inclusions in patients with motor neuron disease carrying reduced and intermediate HTT gene expansions.	Peggy	Schumann
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24069 Pleiotropy and variable penetrance of amyotrophic lateral sclerosis associated with intermediate and full-length CAG-repeat expansion of ATXN2	Anna-Karin	Roos
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24085 Personalised penetrance calculation in families with C9orf72-related amyotrophic lateral sclerosis and frontotemporal dementia	Johnathan	Cooper-Knotk
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24090 Intracisternal Injection of SOD1 Aggregates Induces ALS Pathology in Transgenic Mouse Models	Andrew	Douglas
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24160 The Implication of C9orf72 repeat expansions in GWAS data	Isabelle	Sigfridsson
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24168 Common variant association analyses to identify prognostic loci in Amyotrophic Lateral Sclerosis	Polina	Merbaum
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24185 A Homozygous OPTN mutation causes a heterogeneous disease presentation in a consanguineous family	Johanna	Juansoo
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24188 Variants in FIG4 gene in a cohort of French ALS patients and cell hypervacuolizations supporting its involvement in ALS pathophysiology.	Omar	Keritam
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24204 FUS p.Q23L mutation, a variant of unknown significance and possible non-pathogenic in amyotrophic lateral sclerosis	Patrick	VOURCH
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24209 Comprehensive Genetic Analysis of an Italian Amyotrophic Lateral Sclerosis Cohort	Erica	Stenvall
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24223 Atypical phenotype of amyotrophic lateral sclerosis with double mutation in FUS and TARDBP genes: an insidious case of lower limbs motor neuronopathy	Alessia	Fiorentino
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24245 Improved Diagnosis and Understanding of C9orf72 Repeat Instability in Blood and Brain	Gabriella Maria	Acerra
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24251 Identification and characterization of novel MIF variants with increased stability and reduced inflammatory activity as a potential treatment for ALS	Georg	Haase
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24259 rs1268932 polymorphism in UNC13A as a risk factor in a cohort of Spanish patients with ALS	Shir	Barel
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24261 Genomic analysis of Czech ALS cohort for the incidence of variants in modifying genes	Daniel	Borrego Hernández
Posteression B - Tuesday June 18, 17:45-18:45 hrs	SOD1 enzymatic activity in CSF of ALS patients with and without SOD1 mutations: Discordant SOD1 enzymatic activity in erythrocytes and CSF	Nazli Sila	Kara
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24286 UNC13A in Norwegian patients diagnosed with ALS	Laura	Leykam
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24303 CLINICAL AND MOLECULAR LANDSCAPE OF ALS PATIENTS WITH SOD1 MUTATIONS FROM TURKEY: NOVEL PATHOGENIC VARIANTS AND EXPANDING PHENOTYPES: A SINGLE NEUROMU	Camilla	Novy
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24328 GENETIC LANDSCAPE OF ALS PATIENTS FROM TURKEY: ISTANBUL UNIVERSITY EXPERIENCE	Hacer	Durmus
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24357 Exploring Genetic Biomarkers in a Spanish Cohort: Analysis of 13 Modifying Variants in ALS Progression and Risk	Hacer	Durmus
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24382 Clinical heterogeneity of FALS patients in Serbia	Jose Manuel	Vidal-Taboada
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24385 Investigating the Oligogenic Model of Amyotrophic Lateral Sclerosis	Aleksa	Palibrk
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24392 Exome-wide protein domain-based burden analysis identifies genetic associations with ALS risk	Sarah	Gornall
Posteression B - Tuesday June 18, 17:45-18:45 hrs	Healthcare Resource Utilization (HCRU), Quality of Life (QoL), and Economic Burden Among People with Amyotrophic Lateral Sclerosis (pALS) in Spain	Heather	Marriott
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24028 Healthcare Resource Utilization of Oral Edoxavone-Treated Patients With Amyotrophic Lateral Sclerosis Enrolled in an Administrative Claims Database	Katie	Stenson
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24068 Building neuromuscular assemblies of distinct axial levels from human induced pluripotent stem cells	Małgorzata	Ciepielewska
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24094 Longitudinal head-to-head comparison of different outcome measures in the ALS Methodology Study 999A3003	Melanie	Leboeuf
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24315 A comparison of Amplicon-C9 and Southern blot to identify C9orf72 mosaicism.	Christoph	Neuwirth
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24044 Global analysis of access to genetic counseling and testing by people living with ALS/MND	Emmy	Skelton Kockum
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24110 Report on the International Network for ALS Research and Care (INARC) 2023 meeting and workshop	Martina	de Majo
Posteression B - Tuesday June 18, 17:45-18:45 hrs	Light The Way: Coproduction of an Online Platform for People at Risk of Genetic ALS/FTD via combined Scientific and Patient Advisory Board (SAPAB)	Juliette	Foucher
Posteression B - Tuesday June 18, 17:45-18:45 hrs	Light The Way: Translation of an online platform for genetic education, counseling, and testing into US Spanish to reduce gaps in care	Paul	Wicks
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24296 Advanced Directives in ALS: data and clinical considerations	Paul	Wicks
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24043 Role of Ferroptosis in Amyotrophic Lateral Sclerosis Neuronal Demise	Christian	Lunetta
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24104 Bortezomib as a novel therapy for the treatment of ALS muscle	Muhammad	Ismail
Posteression B - Tuesday June 18, 17:45-18:45 hrs	An in vitro model of SOD1(G93A) microglia to evaluate the therapeutic effect of extracellular vesicles from adipose mesenchymal stem cells	Patricia	Rico
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24055 Immunomodulation in skeletal muscle ameliorates NMJ denervation in the hTDP-43 mouse model of ALS	Mauro	Capriotti
Posteression B - Tuesday June 18, 17:45-18:45 hrs	The novel regulatory role of lncRNA MALAT1 in muscle development and autophagy: towards a nanomedicine strategy for amyotrophic lateral sclerosis.	Bernát	Nágrádi
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24121 Montelukast improves disease outcomes in SOD1G93A female mice by counteracting oligodendrocyte dysfunction and aberrant glial reactivity	Eleonora	Giagnorio
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24228 Developing a gene therapy approach to treat TDP-43 proteinopathies.	Tiziana	Bonifacino
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24260 Putative neuroprotective targets identified in differentially expressed transcripts in astrocytes from symptomatic and asymptomatic C9orf72 Carriers	Laura	Pasetto
Posteression B - Tuesday June 18, 17:45-18:45 hrs	Tk1 mutant zebrafish show increased programmed cell death and dysregulation of critical pathways involved in Amyotrophic Lateral Sclerosis (ALS)	Allan	Shaw
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24065 Characterising activity-related phenotypes in C9orf72 iPSC MNS using optogenetics	Quantin	Raas
Posteression B - Tuesday June 18, 17:45-18:45 hrs	Impact of trauma on presymptomatic C9orf72 carriers and symptomatic patients using hiPSC-derived organoids	Ilai	Gao
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24035 as a double-hit model of neurodegeneration	Karthik	Baskar
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24323 NEK1 regulates ER-mitochondria contacts.	Natalie	Pye
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24161 Comprehensive DNA methylation analysis shows no age acceleration in amyotrophic lateral sclerosis.	Polina	Merbaum
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24383 Dysregulation of muscle cholesterol homeostasis in amyotrophic lateral sclerosis	Flore	Cheguitaume
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24165 Disruption of the Angiotensin-like protein system associates lipid homeostasis with hypothalamic dysfunction in ALS	Flora	Cheguitaume
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24067 Altered Expression of Membrane Proteins in C9orf72 Mutation-Associated ALS and FTD	Urša	Krishnamurthy
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24007 Endothelial TDP-43 controls sprouting angiogenesis and vascular barrier integrity, and its deletion triggers neuroinflammation	Eloi	Montañez
Posteression B - Tuesday June 18, 17:45-18:45 hrs	24353 Activation of polo-like kinase 1 expression in spinal motor neurons underlies the increased vulnerability of spinal motor neurons in FUS-ALS	Andreas	Hermann